Short Interest in BioAge Labs, Inc. (NASDAQ:BIOA) Drops By 34.5%

BioAge Labs, Inc. (NASDAQ:BIOA) saw a significant decrease in short interest in the month of July. As of July 15th, there was short interest totaling 2,451,099 shares, a decrease of 34.5% from the June 30th total of 3,744,445 shares. Based on an average trading volume of 540,360 shares, the days-to-cover ratio is presently 4.5 days. Approximately 6.7% of the company’s stock are sold short.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, July 21st. Needham & Company LLC lowered their price target on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research report on Friday. Wall Street Zen downgraded shares of BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Jefferies Financial Group set a $21.00 price objective on shares of BioAge Labs in a report on Friday. Finally, BTIG Research initiated coverage on shares of BioAge Labs in a research note on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price objective for the company. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $36.57.

BioAge Labs Price Performance

Shares of BIOA stock opened at $9.04 on Friday. The stock’s fifty day moving average price is $20.61 and its 200 day moving average price is $19.51. BioAge Labs has a 1-year low of $4.11 and a 1-year high of $25.95. The company has a market cap of $401.83 million, a price-to-earnings ratio of -3.77 and a beta of 0.61.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. The company had revenue of $2.77 million during the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. As a group, equities research analysts anticipate that BioAge Labs will post -2.68 earnings per share for the current year.

Hedge Funds Weigh In On BioAge Labs

Several hedge funds have recently modified their holdings of BIOA. Janus Henderson Group PLC boosted its stake in BioAge Labs by 411.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock worth $36,597,000 after purchasing an additional 1,685,063 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in BioAge Labs during the 4th quarter valued at approximately $13,892,000. Stempoint Capital LP acquired a new position in BioAge Labs during the 1st quarter valued at approximately $5,923,000. Millennium Management LLC raised its holdings in shares of BioAge Labs by 749.8% in the third quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock worth $1,803,000 after buying an additional 270,479 shares during the last quarter. Finally, Sphera Funds Management LTD. purchased a new position in shares of BioAge Labs in the fourth quarter worth $3,215,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.